Janaína Pontes

Ms. Janaína Pontes

São Paulo State University, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JPJanaína Pontes
Janaína Pontes
ABAnna Beatriz Toledo Borges
Anna Beatriz Toledo Borges
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Bacterial resistance is an emergency public health problem worldwide, compounded by the ability of bacteria to form biofilms, mainly in seriously ill hospitalized patients. The World Health Organization has published a list of priority bacteria that should be studied and, in turn, has encouraged the development of new drugs. Herein, we explain the importance of studying new molecules such as antimicrobial peptides (AMPs) with potential against multi-drug resistant (MDR) and extensively drug-resistant (XDR) bacteria and focus on the inhibition of biofilm formation. This review describes the main causes of antimicrobial resistance and biofilm formation, as well as the main and potential AMP applications against these bacteria. Our results suggest that the new biomacromolecules to be discovered and studied should focus on this group of dangerous and highly infectious bacteria. Alternative molecules such as AMPs could contribute to eradicating biofilm proliferation by MDR/XDR bacteria; this is a challenging undertaking with promising prospects.
2

10 April 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
EJEdson Reinaldo Júnior
Edson Reinaldo Júnior
SNSabrina Fantini do Nascimento
Sabrina Fantini do Nascimento
JPJanaína Pontes
Janaína Pontes
KTKeren Yuki Takada
Keren Yuki Takada
VSVanderson Silva
Vanderson Silva
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Antimicrobial peptides (AMPs) have re-emerged as promising anti-infective agents, particularly against multidrug-resistant bacteria; however, their therapeutic development remains constrained by proteolytic degradation, host cell toxicity, and rapid systemic clearance. Rather than focusing solely on sequence discovery, recent efforts have shifted toward structural and supramolecular modification strategies aimed at improving stability, selectivity, and pharmacological performance. This review critically analyzes intramolecular modifications—including phosphorylation, glycosylation, acetylation, methylation, and backbone cyclization—that modulate peptide conformation and resistance to enzymatic degradation. In parallel, extramolecular approaches such as PEGylation, lipidation, and conjugation to antibiotics, siderophores, or antibodies are examined in the context of enhanced targeting and prolonged bioavailability. Particular emphasis is placed on localized delivery systems, including hydrogels, polymeric films, and nanofibrous scaffolds, which enable spatially controlled administration and mitigate systemic exposure. By integrating evidence from ex vivo and in vivo infection models, this work delineates the translational potential and remaining bottlenecks of chemically engineered AMP platforms for skin and soft tissue infections.